CLINT HOWELL: Open Payments
NPI 1174878433 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,907 in 212 payments from 21 companies in 2025. Trend: 2023 $342 · 2024 $2,959 · 2025 $3,907
Food & beverage: $3,828Education: $79
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $637 |
| Janssen Biotech, Inc. | 33 | $581 |
| Madrigal Pharmaceuticals | 19 | $529 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $496 |
| Gilead Sciences, Inc. | 13 | $223 |
| Lilly USA, LLC | 8 | $184 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $177 |
| QOL Medical, LLC | 6 | $163 |
| Aimmune Therapeutics, Inc. | 7 | $159 |
| Ipsen Biopharmaceuticals, Inc | 13 | $157 |
Products named: TREMFYA, REZDIFFRA, ENTYVIO, RINVOQ, DUPIXENT, OMVOH, Sucraid, LINZESS.
Industry payments across OK — which companies pay providers there.
